Claims for Patent: 9,433,690

Summary for Patent: 9,433,690

Title:	Radiopharmaceutical solutions with advantageous properties
Abstract:	Methods and solutions are describes whereby radiopharmaceutical radium-224 solutions are added complex for scavenging daughter nuclide, which may enhance the overall targeting and reduces uptake of daughter nuclide in normal tissues and cells. This is accomplished without reducing the bone targeting ability of radium. The methods and solutions are convenient to use since the complexation of daughter nuclide can be done in situ in a ready to use radiopharmaceutical solution or, depending on the activity concentration, in a simple kit format by mixing two solutions and store the mixture for typically 1 minute to a few hours before administration to a patient. The use of targeted chelate scavengers for .sup.224Ra daughter nuclide opens up the possibility for using .sup.224Ra based solutions for medical treatments.
Inventor(s):	Larsen; Roy Hartvig (Oslo, NO)
Assignee:	SCIENCONS AS (Oslo, NO)
Application Number:	14/632,849
Patent Claims:	1. A radiopharmaceutical solution comprising a free uncomplexed .sup.224Ra in solution with .sup.212Pb complexed with EDTMP, antibody-conjugated-DOTA, or antibody-conjugated-TCMC. 2. The radiopharmaceutical solution according to claim 1, wherein .sup.212Pb is complexed with a TCMC-conjugated monoclonal antibody. 3. A method of making a radiopharmaceutical solution of claim 1 comprising: mixing a solution comprising free uncomplexed .sup.224Ra and .sup.212Pb complexed with EDTMP, antibody-conjugated-DOTA, or antibody-conjugated-TCMC. 4. A method of treating a skeletal disease comprising: administering the radiopharmaceutical solution of claim 1 to a subject that has a skeletal disease wherein the skeletal disease is a skeletal metastases cancer selected from breast, prostate, kidneys, lung, bone, thyroid, multiple myeloma, primary skeletal, or osteosarcoma. 5. The radiopharmaceutical solution according to claim 1, wherein .sup.212Pb is complexed with EDTMP. 6. The radiopharmaceutical solution according to claim 1, wherein .sup.212Pb is complexed with a DOTA-conjugated monoclonal antibody. 7. The radiopharmaceutical solution according to claim 1, wherein the complexing agent is (Herceptin) TCMC-trastuzumab. 8. The radiopharmaceutical solution according to claim 1, wherein the solution is in a volume of 100 .mu.L to 10 mL and the radioactivity is 100 kBq to 100 MBq.

Details for Patent 9,433,690

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2039-03-29
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2039-03-29
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019		2039-03-29